African medicinal plants against malaria

Slides:



Advertisements
Similar presentations
A Business Proposal and Plan
Advertisements

MICS3 Data Analysis and Report Writing
Understanding the Antimalarials Market in Uganda Rosette Mutambi, HEPS Uganda Martin Auton, Health Action International, The Netherlands ASTMH, December.
A community-based malaria control project An introduction to the project, prepared by: NatashaTamplin and Jamie Edgerton November 2007 UGANDA THE LAMPS.
Student: Song Lijie Advisor: Prashant Yadav Santiago Kraiselburd
Doctors For Life International: An NGO’s perspective on Malaria in Southern Africa Bola Omoniyi, Ph.D. http:
National Malaria Centre of Cambodia Rational Pharmaceutical Management Plus Program World Health Organization European Commission Cambodian Malaria Control.
A Research Active Hospice
Malaria Challenge Introduction to malaria. Malaria is a life threatening disease which is transmitted to humans through the bites of infected female Anopheles.
Malaria in Zambia A refresher Scope of Presentation  Background on Malaria  Overview of malaria in Zambia  Interventions  Impact  Active Case.
DEVELOPMENT IN THE PRODUCTION AND EFFECTIVENESS OF ARTEMISININ Background Information Currently, there is an epidemic of malaria in third world countries,
Malaria Prevention Dietsmann HSE Awareness Campaign.
Geographic Factors and Impacts: Malaria IB Geography II.
Global high-level subsidy for ACT procurement to facilitate low-cost commercial, & other, distribution (allowing effective, affordable home treatment or.
1 Hilary Ranson, Liverpool School of Tropical MedicineNovember 2009 Insecticide resistance and malaria control.
Technology and Health Care HCA 701 November 10, 2005.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
World Health Organization
Start on the T/F quiz at your desk…Let’s see what you already know.
Module 7: Malaria and HIV/AIDS Palliative Care for People Living with HIV/AIDS.
A New Treatment for Malaria: Artemisinin Prof. Dr. Talal Aburjai.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
9/11 “The Malaria epidemic is like loading up seven Boeing 747 airplanes each day then deliberately crashing them into Mt Kilamanjaro” Chairman Malaria.
Access to Medicines: Antimalarials WHO/UNICEF Technical Briefing Seminar 10 October 2007 Silvia Schwarte Supply Chain Management Global Malaria Programme.
Cost Analysis of Management of Malaria Using ACT in the Private Sector of Zimbabwe: a Regulatory Implication Travor Mabugu BPharm (HONS), MSc, MPS School.
Africa Herbal Antimalaria Meeting Nairobi, March 2006 Research on Traditional Medicines used for the Treatment of Malaria in WHO African Region Traditional.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
WHO Traditional Medicine Strategy and Guidelines Dr Arvind Mathur MD, DHA, DNB Cluster Coordinator Family & Community Health WHO-India World Health Organisation.
Introduction To Pharmacy Practice
Working with communities to tackle malaria in Uganda HENRY TITO OKWALINGA PROJECT OFFICER, MALARIA, AMREF UGANDA.
Clinical Audit as Evidence for Revalidation Dr David Scott, GMC Associate, Consultant Paediatrician and Clinical Lead for Children’s Services, East Sussex.
MALARIA TRACK SESSION SUMMARIES_ICIUM 2011 TEAM MEMBERS: EVELYN ANSAH, KOJO YEBOAH-ANTWI, CHARLES EZENDUKA, DAVID OFORI-ADJEI.
Evaluation of home-based management of fever in urban Ugandan children Sarah Staedke London School of Hygiene & Tropical Medicine MU-UCSF Research Collaboration.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
AFRICA HERBAL ANTIMALARIA MEETING ORGANISED BY THE WORLD AGROFORESTRY CENTRE (ICRAF) AND THE ASSOCIATION FOR THE PROMOTION OF TRADITIONAL MEDICINE (PROMETRA.
Improving Access and Quality Use of Medicines in Palliative Care within National Drug Policy, Regulatory, and Funding Frameworks Debra Rowett, Tania Shelby-James,
ACT subsidy- operational pitfalls and opportunities Christopher Whitty Evidence to All-Party Parliamentary Malaria Group 2007.
BLI Research Project By: Tiffany Hou Artemisinin.
Malaria Case management KPA conference. Presentation outline  Introduction  National malaria strategy  Case management targets  AMFm subsidy  The.
ARE PHARMACEUTICAL CORPORATIONS HEROES OR VILLIANS? 2 Lessons
 From time immemorial, malaria has always been a major public health problem in Nigeria and the rest of Africa.  It was a threat to colonialism under.
Malaria treatment policies: the challenge, strategies and the options SOTA, Nairobi, Kenya 12 th June 2002.
Should developing countries continue to use older drugs for essential hypertension? A prescription survey in South Africa suggested that prescribers were.
SUCCESS OR FAILURE? At the moment there is no doubt that the battle against malaria is being lost. This is mainly due to the ability of mosquitoes to develop.
Y. Venkateswara Rao Dabur Research Foundation. Overview  Traditional Knowledge  What can be commercialized?  Why Commercialization?  Commercialization.
| Slide 1 of 25 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.
Issues in malaria diagnosis and treatment May 31, 2007 Jacek Skarbinski, MD Malaria Branch Centers for Disease Control and Prevention.
THE EVIDENCE SANDWICH MODEL Dr. Soumyadeep Bhaumik BioMedical Genomics Centre, Kolkata Research priority setting exercises:
 Begins with a mosquito bite by the infected insect  Malaria symptoms appear about 9 to 14 days after the infectious mosquito bite  Typically, malaria.
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
 Begins with a mosquito bite by the infected insect  Malaria symptoms appear about 9 to 14 days after the infectious mosquito bite  Typically, malaria.
Malaria carried by the Anopheles Mosquito
Steps for the Integration of Traditional Medicine in the National Health Care Delivery System 18 TH ICASA Special Session on Traditional Medicine 1 st.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
1 Mobile Health Plus+ Presented by: Amaresh Sahoo (SIMSR, PGDM ) Prashant Gianani (SIMSR, PGDM )
Seasonal Malaria Chemoprevention: WHO Policy and Perspectives
Off-label Use.
MALARIA.
Health Technology Assessment
Malaria in Tribal Areas
Access to Antimalarial Medicines
Malaria.
Access to Artemisinin-based Antimalarial Medicines
Malaria Prevention Dietsmann HSE Awareness Campaign.
Medicine in third world countries
Regulation of Medical Products & Patient Safety- A Narrative Review
Expert Speak: How Pharma Companies Can Grow Their Business?
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

African medicinal plants against malaria Dr Merlin Willcox, RITAM (Research Initiative on Traditional Antimalarial Methods)

Meeting Objectives To share information To develop a collaborative action programme for Africa-wide production and distribution of appropriate herbal antimalarials

The economics of malaria 2-5 billion febrile episodes a year resembling malaria 500 million cases of malaria 1.1 million deaths 90% of deaths are in African children 58% of deaths in poorest 20% of population

Economics of malaria (2) Up to 75% use traditional herbal medicine as first line treatment Adult course of ACT = $2.4, may reduce to $1 Diagnostic test = $1 Big pharma is not investing in malaria

What is your main objective? To reduce malaria mortality and morbidity? To create jobs and businesses?

What is your market? Poor people in remote areas with no access to modern health care? People who already have access to modern pharmaceuticals? Public health programmes? Herbal prophylactics for ex-pats?

What is an “appropriate” herbal antimalarial? Standardised phytomedicine or home-grown plants? Cheaper than ACTs? Parasite clearance or adequate clinical response? Efficacy or cost-effectiveness? Depends on context….

Types of R&D: Different products, endpoints & methodologies Bioprospecting for active molecules: new leads for conventional drug development Phytomedicines: standardised herbal extracts. Traditional medicine: prepared according to traditional formulations

The competitive advantage of herbal antimalarials Affordable Available Sustainable Reach the parts that modern drugs don’t reach…

Ways of using plants against malaria Insect repellents Vector Control Prophylaxis Treatment

The limitations of traditional medicine There is little clinical data on safety and efficacy Content of active compounds in plants is variable There is no consensus on what plants, preparations and dosages to use These are all remediable, through research…

RITAM Research Initiative on Traditional Anti-Malarial Methods Founded in 1999 by GIFTS of Health, with support from TDR, Rockerfeller www.gifts-ritam.org

Specialist Groups Policy, Advocacy and Funding Preclinical Networking, publications, funding, ethics, intellectual property rights Preclinical Database, guidelines Clinical Development Database, systematic reviews, guidelines Insect repellence and vector control Artemisia annua Task Force Overview of literature Clinical trials planned

The bottom line Herbal insect repellents: some evidence Herbal insecticides: some evidence Herbal treatments: controversial, some clinical evidence Herbal prophylactics: NO clinical evidence

Chicken or egg? “Show us the evidence that it works” Who will pay to generate the evidence?

Herbal treatments No herbal treatments have yet been described to be as efficacious as ACTs for parasite clearance Several herbal treatments could potentially be more cost-effective than ACTs in certain contexts

Where could herbal antimalarials be more cost-effective? Home management Presumptive malaria Semi-immune patients (Adults, children > 5 years old)

When is it unethical to recommend herbal antimalarials? [on current evidence] Non-immune patients Children aged <5 Pregnant women ? If a proven treatment is locally available and affordable to the patient?

The Artemisia annua debate Jansen, 2006: “I believe that the herbal tea approach to artemisinin as a therapy for malaria is totally misleading and should be forgotten as quickly as possible”. Anamed: promoting A. annua cultivation and use as a tea. RITAM response: Need more research

Approaches to A. annua Grow the plant as a cash crop, to sell to pharmaceutical companies, which will make ACTs Grow the plant for local distribution as tea bags Grow the plant in village “green pharmacies” where no other healthcare is available.

Problems with A. annua tea High level of recrudescence at doses tested Optimal method of preparation and dosage not yet defined Variability in artemisinin content

Potential of A. annua tea Cheaper than ACTs Could it be more cost-effective in certain situations, e.g. for home treatment of malaria? Could it be more effective if combined with other herbal antimalarials?

Prophylaxis Many herbal prophylactic preparations are used Almost none have been investigated Some Hausa tribes have lower than expected incidence of malaria (Etkin & Ross, 1991) In the malaria season, they eat plants with antimalarial properties

Neem as a repellent Neem oil on cardboard mats is as effective as synthetic repellents Costs $0.50 per room per year (cf. $25 for synthetic repellents) Also effective topically (2% in coconut oil) for 12 hours Neem oil is larvicidal (LC50 = 3-8ppm)

Phytolacca dodecandra Widespread tropical plant Crushed, powdered berries used as soap and as pesticide Effective at killing schistosomiasis transmitting snails Effective at killing mosquito larvae

Possible roles for medicinal plants Vector control and repellence Prophylaxis Treatment, especially: Presumptive malaria Home management Adults and children >5

Conclusions Herbal antimalarials have huge potential More research IS needed (esp clinical and public health) But who will pay for it? Need to go beyond laboratory studies in order to deliver a health impact.

www.gifts-ritam.org